114 related articles for article (PubMed ID: 1578480)
1. Synthesis and in vitro characterization of novel amino terminally modified oxotremorine derivatives for brain muscarinic receptors.
Garvey DS; Wasicak JT; Chung JY; Shue YK; Carrera GM; May PD; McKinney MM; Anderson D; Cadman E; Vella-Rountree L
J Med Chem; 1992 May; 35(9):1550-7. PubMed ID: 1578480
[TBL] [Abstract][Full Text] [Related]
2. Muscarinic receptor heterogeneity in rat central nervous system. II. Brain receptors labeled by [3H]oxotremorine-M correspond to heterogeneous M2 receptors with very high affinity for agonists.
Gillard M; Waelbroeck M; Christophe J
Mol Pharmacol; 1987 Jul; 32(1):100-8. PubMed ID: 3600611
[TBL] [Abstract][Full Text] [Related]
3. Phenyl-substituted analogues of oxotremorine as muscarinic antagonists.
Nilsson BM; Vargas HM; Ringdahl B; Hacksell U
J Med Chem; 1992 Jan; 35(2):285-94. PubMed ID: 1732545
[TBL] [Abstract][Full Text] [Related]
4. 6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
Daly JW; Gupta TH; Padgett WL; Pei XF
J Med Chem; 2000 Jun; 43(13):2514-22. PubMed ID: 10891110
[TBL] [Abstract][Full Text] [Related]
5. Subtype specificity of the muscarinic receptor-stimulated GTPase response in the rat cortex.
Ghodsi-Hovsepian S; Messer WS; Hoss W
Neurosci Lett; 1990 Mar; 110(1-2):148-54. PubMed ID: 2158014
[TBL] [Abstract][Full Text] [Related]
6. Interactions of agonists with M2 and M4 muscarinic receptor subtypes mediating cyclic AMP inhibition.
McKinney M; Miller JH; Gibson VA; Nickelson L; Aksoy S
Mol Pharmacol; 1991 Dec; 40(6):1014-22. PubMed ID: 1722002
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and functional characterization of novel derivatives related to oxotremorine and oxotremorine-M.
Dallanoce C; Conti P; De Amici M; De Micheli C; Barocelli E; Chiavarini M; Ballabeni V; Bertoni S; Impicciatore M
Bioorg Med Chem; 1999 Aug; 7(8):1539-47. PubMed ID: 10482446
[TBL] [Abstract][Full Text] [Related]
8. Regional differences in the coupling of muscarinic receptors to inositol phospholipid hydrolysis in guinea pig brain.
Fisher SK; Bartus RT
J Neurochem; 1985 Oct; 45(4):1085-95. PubMed ID: 2411866
[TBL] [Abstract][Full Text] [Related]
9. Coupling of subtypes of the muscarinic receptor to adenylate cyclase in the corpus striatum and heart.
Ehlert FJ; Delen FM; Yun SH; Friedman DJ; Self DW
J Pharmacol Exp Ther; 1989 Nov; 251(2):660-71. PubMed ID: 2810116
[TBL] [Abstract][Full Text] [Related]
10. Relative affinities of drugs acting at cholinoceptors in displacing agonist and antagonist radioligands: the NMS/Oxo-M ratio as an index of efficacy at cortical muscarinic receptors.
Freedman SB; Harley EA; Iversen LL
Br J Pharmacol; 1988 Feb; 93(2):437-45. PubMed ID: 3359114
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of M1- and M2-muscarinic drugs on striatal dopamine release and metabolism in freely moving rats.
Xu M; Mizobe F; Yamamoto T; Kato T
Brain Res; 1989 Aug; 495(2):232-42. PubMed ID: 2765928
[TBL] [Abstract][Full Text] [Related]
12. GTP effects in rat brain slices support the non-interconvertability of M1 and M2 muscarinic acetylcholine receptors.
Spencer DG; Horváth E; Traber J; Van Rooijen LA
Life Sci; 1988; 42(9):993-7. PubMed ID: 3343895
[TBL] [Abstract][Full Text] [Related]
13. The synthesis and biochemical pharmacology of enantiomerically pure methylated oxotremorine derivatives.
Trybulski EJ; Zhang J; Kramss RH; Mangano RM
J Med Chem; 1993 Nov; 36(23):3533-41. PubMed ID: 8246221
[TBL] [Abstract][Full Text] [Related]
14. Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine.
Flynn DD; Mash DC
J Pharmacol Exp Ther; 1989 Aug; 250(2):573-81. PubMed ID: 2760841
[TBL] [Abstract][Full Text] [Related]
15. Muscarinic receptor agonist-mediated modulation of neuronal activity in rat cerebral cortex.
Lin Y; Phillis JW
Eur J Pharmacol; 1991 Jul; 200(1):45-52. PubMed ID: 1722754
[TBL] [Abstract][Full Text] [Related]
16. Antimuscarinic oxotremorine analogs distinguish high and low affinity agonist states of muscarinic receptors.
Ringdahl B; Amstutz R; Closse A
Proc West Pharmacol Soc; 1988; 31():57-60. PubMed ID: 3211922
[No Abstract] [Full Text] [Related]
17. The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart.
Ehlert FJ; Delen FM; Yun SH; Liem HA
J Pharmacol Exp Ther; 1990 Apr; 253(1):13-9. PubMed ID: 2329499
[TBL] [Abstract][Full Text] [Related]
18. Reduced high-affinity agonist binding at the M(1) muscarinic receptor in Alzheimer's disease brain: differential sensitivity to agonists and divalent cations.
Ladner CJ; Lee JM
Exp Neurol; 1999 Aug; 158(2):451-8. PubMed ID: 10415152
[TBL] [Abstract][Full Text] [Related]
19. L-689,660, a novel cholinomimetic with functional selectivity for M1 and M3 muscarinic receptors.
Hargreaves RJ; McKnight AT; Scholey K; Newberry NR; Street LJ; Hutson PH; Semark JE; Harley EA; Patel S; Freedman SB
Br J Pharmacol; 1992 Oct; 107(2):494-501. PubMed ID: 1422595
[TBL] [Abstract][Full Text] [Related]
20. Bilateral changes in neocortical [3H]pirenzepine and [3H]oxotremorine-M binding following unilateral lesions of the rat nucleus basalis magnocellularis: an autoradiographic study.
Atack JR; Wenk GL; Wagster MV; Kellar KJ; Whitehouse PJ; Rapoport SI
Brain Res; 1989 Apr; 483(2):367-72. PubMed ID: 2706526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
